DR. REDDY'S INTRODUCES DOXOFYLLINE IN INDIA

A A

Indian drugmaker Dr. Reddy's has introduced Doxofylline, a novel second-generation xanthine bronchodilator, in India, the company reported. Doxofylline, marketed under the brand name Doxobid, will be available in 400-mg dosages.

Doxobid, intended to treat patients suffering from asthma and chronic obstructive pulmonary disease (COPD), inhibits phosphodiesterase activities and has been shown to have a better safety profile than various other COPD medications. The bronchodilating activities of the drug have been demonstrated in clinical trials involving patients with either bronchial asthma or COPD, Dr. Reddy's reported.